This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Amwell Shares Rise After Expansion of Portfolio With Hello Heart
by Zacks Equity Research
AMWL adds Hello Heart to its clinical programs, offering heart health solutions to members with high blood pressure or cholesterol via its Converge platform.
DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?
by Zacks Equity Research
DVA's strong performance and growth strategies, including patient-centric care and international expansion, position it well for continued success despite potential risks.
Merit Medical Stock Gains 24.7% Year to Date: What's Behind the Rally?
by Zacks Equity Research
MMSI shows strong growth momentum with a robust product portfolio and recent acquisitions, positioning itself well in competitive healthcare markets.
Trinity Biotech Shares Surge on Positive Pre-Pivotal Clinical CGM Trial
by Zacks Equity Research
TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, setting the stage for further development in 2025.
Rockwell Medical, Inc. (RMTI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Rockwell Medical Stock Surges 108.5% YTD: Should You Snap it Up Now?
by Urmimala Biswas
RMTI continues to outperform its peers, banking on its focus on optimizing business to drive sustainable profitability and meaningful cash flow generation.
Rockwell Medical (RMTI) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Rockwell Medical (RMTI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Fast-paced Mover Rockwell Medical (RMTI) Is a Great Choice for Value Investors
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Rockwell Medical (RMTI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Rockwell Medical, Inc. (RMTI) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Rockwell Medical, Inc. (RMTI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Fast-paced Momentum Stock Rockwell Medical (RMTI) Is Still Trading at a Bargain
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Rockwell Medical (RMTI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Rockwell Medical (RMTI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 125% and 12.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Jushi Holdings Inc. (JUSHF) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Jushi Holdings Inc. (JUSHF) delivered earnings and revenue surprises of 83.33% and 3.81%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 200% and 11.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus (EOLS) delivered earnings and revenue surprises of -75% and 2.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 60% and 7.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
InMode (INMD) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
InMode (INMD) delivered earnings and revenue surprises of 12.50% and 0.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Rockwell Medical (RMTI) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the latest trading session, Rockwell Medical (RMTI) closed at $1.65, marking a +1.85% move from the previous day.
Rockwell Medical (RMTI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 125% and 0.01%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Rockwell Medical (RMTI) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
Rockwell Medical (RMTI) concluded the recent trading session at $1.54, signifying a +1.32% move from its prior day's close.
Rockwell Medical (RMTI) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Rockwell Medical (RMTI) stood at $1.48, denoting a +0.68% change from the preceding trading day.
Rockwell Medical (RMTI) Flat As Market Gains: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Rockwell Medical (RMTI) stood at $1.37, denoting no change from the preceding trading day.
Why Rockwell Medical (RMTI) Dipped More Than Broader Market Today
by Zacks Equity Research
In the closing of the recent trading day, Rockwell Medical (RMTI) stood at $1.34, denoting a -0.74% change from the preceding trading day.
Rockwell Medical (RMTI) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Rockwell Medical (RMTI) closed at $1.29 in the latest trading session, marking no change from the prior day.
Rockwell Medical (RMTI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 41.67% and 0.43%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?